CA3062452C - Compositions, combinaisons et methodes connexes pour le traitement de troubles neurologiques - Google Patents

Compositions, combinaisons et methodes connexes pour le traitement de troubles neurologiques Download PDF

Info

Publication number
CA3062452C
CA3062452C CA3062452A CA3062452A CA3062452C CA 3062452 C CA3062452 C CA 3062452C CA 3062452 A CA3062452 A CA 3062452A CA 3062452 A CA3062452 A CA 3062452A CA 3062452 C CA3062452 C CA 3062452C
Authority
CA
Canada
Prior art keywords
compound
hydrogen
phenoxy
propan
deramciclane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3062452A
Other languages
English (en)
Other versions
CA3062452A1 (fr
Inventor
Sreenivasarao Vepachedu
Hans J. MOEBIUS
Anton Bespalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exciva GmbH
Original Assignee
Exciva GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/fr
Application filed by Exciva GmbH filed Critical Exciva GmbH
Priority to CA3138116A priority Critical patent/CA3138116A1/fr
Publication of CA3062452A1 publication Critical patent/CA3062452A1/fr
Application granted granted Critical
Publication of CA3062452C publication Critical patent/CA3062452C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés de la formule I, des sels pharmaceutiquement acceptables de ces derniers, leurs énantiomères, leurs métabolites, leurs dérivés, leurs promédicaments, leurs sels pharmaceutiquement acceptables, leurs N-oxydes, ou une association de ces derniers, des procédés et des intermédiaires pour leur préparation, des compositions les contenant, et leurs utilisations. L'invention concerne des compositions pharmaceutiques comprenant un composé de la formule I, ou ses énantiomères, ses métabolites, ses dérivés, ses promédicaments, ses sels d'addition d'acide, ses sels pharmaceutiquement acceptables, ou ses N-oxydes, ou une association de ces derniers, le composé étant un agent ou un ligand double et/ou un triple pour les récepteurs CYP2D6, 5-HT2A et/ou 5 HT2C, et/ou l'acétylcholinestérase.
CA3062452A 2017-05-04 2018-05-03 Compositions, combinaisons et methodes connexes pour le traitement de troubles neurologiques Active CA3062452C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3138116A CA3138116A1 (fr) 2017-05-04 2018-05-03 Nouvelles compositions, combinaisons et methodes connexes

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
US62/501,696 2017-05-04
USPCT/US2017/048748 2017-08-25
PCT/US2017/048748 WO2018039642A1 (fr) 2016-08-26 2017-08-25 Compositions et procédés associés
TW106129169 2017-08-28
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US62/634,162 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US62/636,099 2018-02-27
US62/635,554 2018-02-27
US201862636171P 2018-02-28 2018-02-28
US62/636,171 2018-02-28
PCT/US2018/030978 WO2018204713A1 (fr) 2017-05-04 2018-05-03 Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3138116A Division CA3138116A1 (fr) 2017-05-04 2018-05-03 Nouvelles compositions, combinaisons et methodes connexes

Publications (2)

Publication Number Publication Date
CA3062452A1 CA3062452A1 (fr) 2018-11-08
CA3062452C true CA3062452C (fr) 2023-10-24

Family

ID=65431106

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3138116A Pending CA3138116A1 (fr) 2017-05-04 2018-05-03 Nouvelles compositions, combinaisons et methodes connexes
CA3062452A Active CA3062452C (fr) 2017-05-04 2018-05-03 Compositions, combinaisons et methodes connexes pour le traitement de troubles neurologiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3138116A Pending CA3138116A1 (fr) 2017-05-04 2018-05-03 Nouvelles compositions, combinaisons et methodes connexes

Country Status (13)

Country Link
EP (1) EP3618819A4 (fr)
JP (2) JP7514078B2 (fr)
KR (2) KR102444803B1 (fr)
CN (1) CN110831584B (fr)
AU (2) AU2018261654A1 (fr)
BR (1) BR112019022902A2 (fr)
CA (2) CA3138116A1 (fr)
IL (1) IL270326B2 (fr)
MA (1) MA49464A (fr)
RU (1) RU2760558C9 (fr)
TW (1) TWI787260B (fr)
WO (1) WO2018204713A1 (fr)
ZA (1) ZA201908006B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022526101A (ja) * 2019-03-18 2022-05-23 アヴェニール ファーマシューティカルズ， インコーポレイテッド 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
WO2020246143A1 (fr) * 2019-06-06 2020-12-10 Jsr株式会社 Composition de résine sensible au rayonnement, procédé de formation d'un modèle de réserve, et composé
EP4153564A4 (fr) 2020-05-19 2024-06-19 Cybin IRL Limited Dérivés de tryptamine deutérés et procédés d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
KR20080097443A (ko) 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN105491885B (zh) * 2013-03-07 2018-09-25 思想实验室有限责任公司 疼痛药物组合及其用途
WO2014145568A2 (fr) * 2013-03-15 2014-09-18 Kinemed, Inc. Biomarqueurs
CN109890371A (zh) * 2016-08-26 2019-06-14 斯瑞尼瓦萨饶·韦帕切杜 组合物及其方法

Also Published As

Publication number Publication date
RU2019137004A3 (fr) 2021-06-04
AU2018261654A1 (en) 2019-11-14
BR112019022902A2 (pt) 2020-05-19
EP3618819A4 (fr) 2021-01-20
RU2760558C9 (ru) 2022-02-22
CA3138116A1 (fr) 2018-11-08
IL270326B2 (en) 2023-02-01
IL270326B (en) 2022-10-01
CA3062452A1 (fr) 2018-11-08
JP7514078B2 (ja) 2024-07-10
IL270326A (fr) 2018-05-03
AU2021215274A1 (en) 2021-09-02
TWI787260B (zh) 2022-12-21
MA49464A (fr) 2020-04-29
CN110831584A (zh) 2020-02-21
RU2019137004A (ru) 2021-06-04
ZA201908006B (en) 2021-04-28
CN110831584B (zh) 2023-03-10
RU2760558C2 (ru) 2021-11-29
KR20210130827A (ko) 2021-11-01
KR20200062078A (ko) 2020-06-03
TW201842902A (zh) 2018-12-16
JP2023143940A (ja) 2023-10-06
AU2021215274B2 (en) 2022-11-03
JP2020518617A (ja) 2020-06-25
KR102444803B1 (ko) 2022-09-19
EP3618819A1 (fr) 2020-03-11
WO2018204713A1 (fr) 2018-11-08

Similar Documents

Publication Publication Date Title
US20210228508A1 (en) Compositions and methods thereof
AU2021215274B2 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2023513679A (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
US20200069674A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2011502977A (ja) 多発性硬化症および自己免疫性脊髄炎の治療における３，１１Ｂ−ｃｉｓ−ジヒドロテトラベナジンの使用
AU2009259038A1 (en) Dihydrotetrabenanzine for the treatment of anxiety
JP2024508545A (ja) セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
JP2008517901A (ja) 経口で有効なカンナビノイド類似体
JPH0723387B2 (ja) ピペラジンカルボン酸、その製造方法およびそれを含有する医薬組成物
US20220296586A1 (en) Novel compositions, combinations, and methods thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104

EEER Examination request

Effective date: 20191104